Overview
DIA 2015 51st Annual Meeting: Develop. Innovate. Advance.
The DIA 2015 51st Annual Meeting brings together a global community of life sciences professionals at all levels and across all disciplines all with a common goal to foster innovation that will lead to the development of safe and effective medical products and therapies to patients.
The DIA Annual Meeting provides the best opportunity to meet with people from around the world, share your views and knowledge, network, and build new relationships.
Program Committee
-
Christopher P. Austin, MD CEO Partner
Flagship Pioneering, United States -
Michael Rosenblatt, MD Chief Medical Officer
Flagship Pioneering, United States -
J. Lynn Bass, PharmD, RPh Senior Director, Medical Science Liaisons
BridgeBio, United States -
Daniel Bollag, PhD Chief Strategy Officer
Ocular Therapeutics, United States -
Linda Bowen, MSc, RAC Executive Director and Head of the Regulatory Centers of Excellence
Seagen Inc., United States -
Jonca Bull, MD Vice President, Regulatory Consulting
PPD, United States -
Bill Byrom, PhD Vice President, Product Intelligence and Positioning; Principal, eCOA Science
Signant Health , United Kingdom -
Joy A. Cavagnaro, PhD President
Access BIO, United States -
Karla Childers, MS Head, Bioethics-Based Science and Technology Policy
Johnson & Johnson, United States -
Leah Christl, PhD Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy
Amgen, United States -
Betsy Fallen, RN Consultant
BAFallen Consulting LLC, United States -
Ron Fitzmartin, PhD, MBA Senior Informatics Advisor, Office of Regulatory Operations, CBER
FDA, United States -
Michael Folkendt, MS Associate Director for Regulatory Affairs, OPRO, OPQ, CDER
FDA, United States -
Elizabeth E. Garrard, PharmD Executive Vice President, Global Safety Operations
Clinipace Worldwide, United States -
Jonathan Haddad, MPH HIV Disease Area Head, Clinical Statistics
GlaxoSmithKline, United States -
Martin Harvey Allchurch, LLM Head of International Affairs
European Medicines Agency, Netherlands -
Jonathan Solomon Helfgott, MS Executive Director, Global Regulatory/Clinical Affairs
Stage 2 Innovations, United States -
Deborah J. Henderson, MSN Head, Global Regulatory Policy
Merck & Co., Inc., United States -
Rima Izem, PhD Associate Director Statistical Methodology
Novartis, Switzerland -
Janet Jenkins-Showalter Head, US Regulatory Policy
Genentech, A Member of the Roche Group, United States -
John Kamp Washington Counsel
Coalition For Healthcare Communication (CHC), United States -
Ellen Kelso Head, Knowledge Strategy
KSE Ltd., United States -
Lynn King, MHA Chief Operating Officer
M3 Wake Research, Inc, United States -
Agnes Klein, MD Senior Medical Advisor
Health Canada, Canada -
Stephen Knowles, MD, MRCP Chief Medical Officer
Halozyme Therapeutics, United States -
Mark Kryah, PMP Executive Director, Program Team Leader, Program and Portfolio Management
Ultragenyx Pharmaceutical Inc., United States -
JeanMarie Markham Chief Executive Officer
Clinlogix, United States -
Philomena McArthur, JD VP, Global Policies, Procedures & Training, Health Care Compliance & Privacy
Johnson & Johnson International, United States -
Ann Meeker-O'Connell, MS Director, Office of Clinical Policy, Office of Clinical Policy and Programs, OC
FDA, United States -
Jon Meyer, MBA, MSc Co-Founder and Managing Member
Life Science Strategy Group, LLC, United States -
Mary Murray, MBA, MS Family Caregiver
Independent Consultant, United States -
Bob Muzerall Vice President, Sales & Sales Training
AMPLEXOR Life Sciences, LLC, United States -
Nancy Bradish Myers, JD CEO and Founder
Catalyst Healthcare Consulting, Inc, United States -
Jane Elizabeth Myles, MSc Program Director
Decentralized Trials and Research Alliance (DTRA), United States -
Roger Nosal, PhD Vice President, Head of Global CMC
Pfizer Inc, United States -
Lisa Palladino-Kim, MS Program Director / Lecturer
Rutgers School of Health Professions Clin Research Mgmt, United States -
Pradip Paul, MD, MS Consultant
Strategic Pharmacovigilance and Risk Management, United States -
Kirsten H. Paulson, MS, RAC
Pfizer, Inc., United States -
Julia Petses, PharmD Global Head, Medical Information Excellence and SEC Established and Rare Franchi
Novartis, United States -
Christine Pierre, RN President
Society for Clinical Research Sites, United States -
James E. Polli, PhD Prof, Ralph F Shangraw/Noxell Endowed Chair in Industrial Pharmacy/Pharmaceutic
University of Maryland School of Pharmacy, United States -
Sarah Pope Miksinski, PhD Executive Director, CMC Regulatory Affairs
Gilead Sciences, United States -
Badri Rengarajan, MD Life Sciences
Jazz Pharmaceuticals, United States -
Matthew D. Rotelli, PhD, MS Vice President, Bioethics
Eli Lilly and Company, United States -
Leslie Sam President
Leslie Sam and Associates, LLC, United States -
Abdul J. Sankoh, PhD, MA, MS Vice President, Data Science
Sage Therapeutics, Inc. , United States -
Suzanne Sensabaugh, MBA, MS President and Principal Consultant
HartmannWillner LLC, United States -
Ashley F. Slagle, PhD, MS Principal, Scientific and Regulatory Consulting
Aspen Consulting, LLC, United States -
Nancy Pire Smerkanich, DrSc, MS Assistant Professor Regulatory & Quality Sciences
University of Southern California School of Pharmacy, United States -
Maureen Smith Patient Advocate / Secretary
Canadian Organization For Rare Disorders (CORD), Canada -
William B. Smith, MD CEO
Alliance for Multispecialty Research, LLC , United States -
Ling Su, PhD Research Fellow
Shenyang Pharmaceutical University, Yeehong Business School, China -
Sameer Thapar, PharmD, RPh Global Pharmacovigilance Director
Oracle Health Sciences, United States -
Toshiyoshi Tominaga, PhD Project Professor
Keio University Hospital, Japan -
Linda Fossati Wood President
MedWrite, Inc., United States
Have an account?